亚太药业：2025年前三季度归属于上市公司股东的净利润同比增长2909.49%

Group 1 - The core point of the article is that Asia-Pacific Pharmaceutical reported a significant decline in revenue for the first three quarters of 2025, while net profit saw an extraordinary increase compared to the previous year [2] Group 2 - For the first three quarters of 2025, the company achieved a revenue of 228,305,775.20 yuan, representing a year-on-year decrease of 25.59% [2] - The net profit attributable to shareholders of the listed company was 97,195,012.22 yuan, showing a remarkable year-on-year growth of 2909.49% [2]